Published on 22 Nov 2023 on Zacks via Yahoo Finance
Repare Therapeutics (RPTX) Rises 34% in a Week: Here's Why
Repare Therapeutics Inc. RPTX is using its genome-wide, CRISPR-enabled SNIPRx platform to discover and develop highly targeted cancer therapies that cater to genomic instability, including DNA damage repair.
The company currently has two candidates in its clinical pipeline, camonsertib, an ATR inhibitor and lunresertib, a PKMYT1 Inhibitor. These two candidates are currently undergoing early-mid-stage development in various cancer indications.
Last week, Repare announced that two additional candidates, RP-1664 and RP-3467, are likely to enter early-stage clinical development in 2024. Following the news, shares of the company have surged 34.2% in the past week compared with the industry’s 1.7% rise.